Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).

Garcia-Donas J, Garrigos L, Lainez N, Santaballa A, Redondo A, Cueva JF, Rubio MJ, Prieto M, Lopez-Guerrero JA, Garcia-Casado Z, Barquin A, Grande E, Alia EG, Sevillano E, Bover I, Grazioso TP, Sanchez-Escribano R, Hurtado A, Navarro P, Rodriguez-Moreno JF

Open source

DOI: 10.1007/s12094-024-03827-4
Published: 2025 Jul
Container: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12094-024-03827-4,
  title = {Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).},
  author = {Garcia-Donas J and Garrigos L and Lainez N and Santaballa A and Redondo A and Cueva JF and Rubio MJ and Prieto M and Lopez-Guerrero JA and Garcia-Casado Z and Barquin A and Grande E and Alia EG and Sevillano E and Bover I and Grazioso TP and Sanchez-Escribano R and Hurtado A and Navarro P and Rodriguez-Moreno JF},
  year = {2025},
  journal = {Clinical \& translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},
  doi = {10.1007/s12094-024-03827-4},
  url = {https://doi.org/10.1007/s12094-024-03827-4}
}

RIS

TY  - JOUR
TI  - Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).
AU  - Garcia-Donas J
AU  - Garrigos L
AU  - Lainez N
AU  - Santaballa A
AU  - Redondo A
AU  - Cueva JF
AU  - Rubio MJ
AU  - Prieto M
AU  - Lopez-Guerrero JA
AU  - Garcia-Casado Z
AU  - Barquin A
AU  - Grande E
AU  - Alia EG
AU  - Sevillano E
AU  - Bover I
AU  - Grazioso TP
AU  - Sanchez-Escribano R
AU  - Hurtado A
AU  - Navarro P
AU  - Rodriguez-Moreno JF
PY  - 2025
JO  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
DO  - 10.1007/s12094-024-03827-4
UR  - https://doi.org/10.1007/s12094-024-03827-4
ER  -

APA

J, G., L, G., N, L., A, S., A, R., JF, C., MJ, R., M, P., JA, L., Z, G., A, B., E, G., EG, A., E, S., I, B., TP, G., R, S., A, H., P, N., & JF, R. (2025). Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. https://doi.org/10.1007/s12094-024-03827-4

Source records

pubmed · retrieved 2026-09-25T06:30:01.694Z